Combination Antibody Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region

In a recent report released by it has been revealed that the chemotherapy/antibody segment of the global combination antibody therapy market is poised for remarkable growth over the forecast period. The segment, which accounted for nearly 40% of the market share by the end of 2031, is anticipated to exhibit a staggering Compound Annual Growth Rate (CAGR) of 8.5% in terms of value, projecting a valuation close to US$ 35 billion in 2024.

Rising Cancer Incidence to Drive Segment's Ascension

One of the primary drivers propelling the growth of the chemotherapy/antibody segment is the escalating incidence of cancer worldwide. With cancer ranking as the second leading cause of mortality globally, the toll it exacts on human lives has surged significantly in recent years. According to the World Health Organization (WHO), over 8 million deaths annually are attributed to cancer, with a forecast of nearly 70% increase in new cancer cases over the next two decades.

Unique Treatment Needs Call for Chemotherapy

Each type of cancer necessitates a tailored approach to treatment, and chemotherapy stands as a cornerstone in the fight against this relentless disease. The capability of chemotherapy to target cancer cells throughout the body addresses the urgent need for comprehensive treatment modalities, thus bolstering the growth of the chemotherapy/antibody segment.

Efficacy Reigns Supreme: Combination Antibody Therapies at the Helm

In contrast to conventional therapies like radiation or surgery, combination antibody therapies, particularly chemotherapy/antibody, have emerged as more efficacious alternatives. While radiation therapy and surgery predominantly target specific areas, combination antibody therapy operates systemically, ensuring a more comprehensive assault on cancer cells.

Awareness and Education: Catalysts for Growth

The burgeoning awareness among individuals regarding available cancer treatment options further fuels the expansion of the chemotherapy/antibody segment. As knowledge dissemination continues to grow, more individuals are empowered to make informed decisions regarding their healthcare, thereby driving demand for innovative therapies.

APAC Region Poised for Significant Value Uptick

While North America continues to dominate the chemotherapy/antibody segment, the APAC (Asia-Pacific) region is poised for exponential growth. With market shares exceeding 40% in Latin America and APAC, the chemotherapy/antibody segment is projected to experience a remarkable surge in the APAC region, reaching close to US$ 6 billion in 2024.

Key Players Pave the Way with Novel Therapies

In a bid to combat chronic Lymphocytic Leukemia (CLL), key players in the industry have unveiled groundbreaking combination drugs. Biogen Inc., a U.S.-based pharmaceutical company, made headlines in 2008 with the successful Phase III clinical trials of Rituxan. This drug, in combination with chemotherapy, demonstrated notable improvements in progression-free survival for patients with relapsed CLL. Subsequently, in 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fludarabine and cyclophosphamide (FC) for treating the most prevalent form of adult leukemia.

Market Dynamics: Key Players and Revenue Share

The global combination antibody therapy market is primarily dominated by the top 10 key players, who collectively contribute approximately 80% of the market's revenue share. This leaves the remaining players to account for the remaining 20% revenue share. Such dynamics underscore the significance of strategic partnerships and innovation in shaping the landscape of the combination antibody therapy market.

Key players in the market are:

• Biogen Inc.
• Roche Holdings AG
• Seattle Genetics Inc.
• Amgen incorporated
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Novartis AG
• Sanofi
• Celgene Corp
• Genmab A/S
• Others.

Market segmentation

By combination, the market is segmented into:

• Chemotherapy/Antibody
• Antibody/Antibody
• Conjugated Antibodies
• Bispecific Antibodies

By application, the market is segmented into:

• Lung Cancer
• Blood Cancer
• Lymphoma
• Leukemia
• Myeloma
• Breast Cancer
• Colorectal Cancer
• Others

By end user, the market is segmented into:

• Hospitals
• Cancer research institutes
• Clinics
• ASCs

By region, the market is segmented into:

• North America
• Latin America
• Europe
• APAC
• MEA

This product will be delivered within 1-3 business days.